The cancer drug Rituxan cut multiple sclerosis lesions and relapses in a small clinical trial; its developers, Genentech and Biogen Idec, hope to establish its efficacy in larger trials. Report [1]
The cancer drug Rituxan cut multiple sclerosis lesions and relapses in a small clinical trial; its developers, Genentech and Biogen Idec, hope to establish its efficacy in larger trials. Report [1]
Links:
[1] http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2008/02/14/BU7GV1LEF.DTL